Neoadjuvant therapy for pancreatic cancer: The Duke experience

Rebekah R. White, Douglas Tyler

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil(5FU)-based chemoradiation therapy (CRT). Approximately 20% of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20% of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36%. This article reviews the authors' experience and the lessons learned from it.

Original languageEnglish (US)
Pages (from-to)675-684
Number of pages10
JournalSurgical Oncology Clinics of North America
Volume13
Issue number4
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Therapeutics
Fluorouracil
Laparotomy
Disease Progression
Survival Rate
Morbidity
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Neoadjuvant therapy for pancreatic cancer : The Duke experience. / White, Rebekah R.; Tyler, Douglas.

In: Surgical Oncology Clinics of North America, Vol. 13, No. 4, 10.2004, p. 675-684.

Research output: Contribution to journalArticle

@article{818b5aff45d04f4a99c99c78110b23a1,
title = "Neoadjuvant therapy for pancreatic cancer: The Duke experience",
abstract = "The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil(5FU)-based chemoradiation therapy (CRT). Approximately 20{\%} of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20{\%} of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36{\%}. This article reviews the authors' experience and the lessons learned from it.",
author = "White, {Rebekah R.} and Douglas Tyler",
year = "2004",
month = "10",
doi = "10.1016/j.soc.2004.06.001",
language = "English (US)",
volume = "13",
pages = "675--684",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant therapy for pancreatic cancer

T2 - The Duke experience

AU - White, Rebekah R.

AU - Tyler, Douglas

PY - 2004/10

Y1 - 2004/10

N2 - The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil(5FU)-based chemoradiation therapy (CRT). Approximately 20% of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20% of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36%. This article reviews the authors' experience and the lessons learned from it.

AB - The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil(5FU)-based chemoradiation therapy (CRT). Approximately 20% of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20% of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36%. This article reviews the authors' experience and the lessons learned from it.

UR - http://www.scopus.com/inward/record.url?scp=4444220500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444220500&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2004.06.001

DO - 10.1016/j.soc.2004.06.001

M3 - Article

C2 - 15350941

AN - SCOPUS:4444220500

VL - 13

SP - 675

EP - 684

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 4

ER -